P.S. Good news is that Gilead has disputed the FT article on the China Remdesivir study and says they terminated the trial for “low-enrollment” and other technical reasons rather than a failure to achieve positive outcomes. There are some other ongoing clinical trials of that anti-viral drug in the U.S. that still might show some efficacy.
Menu